Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma [featured_image] Download is available until [expire_date] Version Download 2 File Size 852.75 KB File Count 1 Create Date 29/09/2022 Last Updated 29/09/2022 Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma